These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 23720275)

  • 1. HEXIM1: a new player in myocardial hypertrophy?
    Catalucci D; Condorelli G
    Cardiovasc Res; 2013 Jul; 99(1):1-3. PubMed ID: 23720275
    [No Abstract]   [Full Text] [Related]  

  • 2. Inducible re-expression of HEXIM1 causes physiological cardiac hypertrophy in the adult mouse.
    Montano MM; Desjardins CL; Doughman YQ; Hsieh YH; Hu Y; Bensinger HM; Wang C; Stelzer JE; Dick TE; Hoit BD; Chandler MP; Yu X; Watanabe M
    Cardiovasc Res; 2013 Jul; 99(1):74-82. PubMed ID: 23585471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAMTA in cardiac hypertrophy.
    Schwartz RJ; Schneider MD
    Cell; 2006 May; 125(3):427-9. PubMed ID: 16678087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NRSF regulates the developmental and hypertrophic changes of HCN4 transcription in rat cardiac myocytes.
    Kuratomi S; Kuratomi A; Kuwahara K; Ishii TM; Nakao K; Saito Y; Takano M
    Biochem Biophys Res Commun; 2007 Feb; 353(1):67-73. PubMed ID: 17173866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SH2B1: a new player in the regulation of cardiac hypertrophic response in failing hearts.
    Ikeda Y; Takimoto E; Komuro I
    Cardiovasc Res; 2015 Jul; 107(2):197-9. PubMed ID: 26077625
    [No Abstract]   [Full Text] [Related]  

  • 6. Exosomes as New Intercellular Mediators in Development and Therapeutics of Cardiomyocyte Hypertrophy.
    Huang Q; Cai B
    Adv Exp Med Biol; 2017; 998():91-100. PubMed ID: 28936734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yin Yang 1 represses alpha-myosin heavy chain gene expression in pathologic cardiac hypertrophy.
    Mariner PD; Luckey SW; Long CS; Sucharov CC; Leinwand LA
    Biochem Biophys Res Commun; 2005 Jan; 326(1):79-86. PubMed ID: 15567155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heat shock transcription factor 1 protects heart after pressure overload through promoting myocardial angiogenesis in male mice.
    Zou Y; Li J; Ma H; Jiang H; Yuan J; Gong H; Liang Y; Guan A; Wu J; Li L; Zhou N; Niu Y; Sun A; Nakai A; Wang P; Takano H; Komuro I; Ge J
    J Mol Cell Cardiol; 2011 Nov; 51(5):821-9. PubMed ID: 21854784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LIM and cysteine-rich domains 1 regulates cardiac hypertrophy by targeting calcineurin/nuclear factor of activated T cells signaling.
    Bian ZY; Huang H; Jiang H; Shen DF; Yan L; Zhu LH; Wang L; Cao F; Liu C; Tang QZ; Li H
    Hypertension; 2010 Feb; 55(2):257-63. PubMed ID: 20026769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pleiotropic and puzzling effects of ATF3 in maladaptive cardiac remodeling.
    Zhou H; Yuan Y; Ni J; Guo H; Deng W; Bian ZY; Tang QZ
    Int J Cardiol; 2016 Mar; 206():87-8. PubMed ID: 26780683
    [No Abstract]   [Full Text] [Related]  

  • 11. Regulation of cardiac hypertrophy by intracellular signalling pathways.
    Heineke J; Molkentin JD
    Nat Rev Mol Cell Biol; 2006 Aug; 7(8):589-600. PubMed ID: 16936699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multifarious molecular signaling cascades of cardiac hypertrophy: can the muddy waters be cleared?
    Balakumar P; Jagadeesh G
    Pharmacol Res; 2010 Nov; 62(5):365-83. PubMed ID: 20643208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitochondria and Cardiac Hypertrophy.
    Facundo HDTF; Brainard RE; Caldas FRL; Lucas AMB
    Adv Exp Med Biol; 2017; 982():203-226. PubMed ID: 28551789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apelin/APJ system: A bifunctional target for cardiac hypertrophy.
    Lu L; Wu D; Li L; Chen L
    Int J Cardiol; 2017 Mar; 230():164-170. PubMed ID: 27979574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromatin remodeling permits cardiac hypertrophy to develop.
    van Berlo JH
    J Mol Cell Cardiol; 2015 Dec; 89(Pt B):119-21. PubMed ID: 26523518
    [No Abstract]   [Full Text] [Related]  

  • 16. Letter concerning: 'Enhanced expression of DYRK1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo'.
    da Costa Martins PA; De Windt LJ
    Cardiovasc Res; 2011 Sep; 91(4):742-3; author reply 743-4. PubMed ID: 21795320
    [No Abstract]   [Full Text] [Related]  

  • 17. Unexpected cardiac hypertrophy by epidermal growth factor receptor silencing.
    Eguchi A; Eguchi S; Tilley DG
    Hypertension; 2013 May; 61(5):e46. PubMed ID: 23547237
    [No Abstract]   [Full Text] [Related]  

  • 18. Class II HDACs mediate CaMK-dependent signaling to NRSF in ventricular myocytes.
    Nakagawa Y; Kuwahara K; Harada M; Takahashi N; Yasuno S; Adachi Y; Kawakami R; Nakanishi M; Tanimoto K; Usami S; Kinoshita H; Saito Y; Nakao K
    J Mol Cell Cardiol; 2006 Dec; 41(6):1010-22. PubMed ID: 17011572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Astragaloside IV protects against isoproterenol-induced cardiac hypertrophy by regulating NF-κB/PGC-1α signaling mediated energy biosynthesis.
    Zhang S; Tang F; Yang Y; Lu M; Luan A; Zhang J; Yang J; Wang H
    PLoS One; 2015; 10(3):e0118759. PubMed ID: 25738576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a growth factor that rejuvenates the heart.
    Musunuru K
    Circ Cardiovasc Genet; 2013 Aug; 6(4):435-6. PubMed ID: 23963162
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.